Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631024 | 0.88 | SIGMAR1 (0.42) | GAASIGMAR1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL13434259 | 0.88 | SIGMAR1 (0.42) | GAASIGMAR1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL13434264 | 0.88 | SIGMAR1 (0.42) | GAASIGMAR1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL5987218 | 0.88 | SIGMAR1 (0.42) | GAASIGMAR1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL13434260 | 0.83 | ALDH1A1 (0.41) | GAASIGMAR1ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL12361787 | 0.83 | ALDH1A1 (0.41) | GAASIGMAR1ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL13630926 | 0.83 | ALDH1A1 (0.41) | GAASIGMAR1ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL13631280 | 0.83 | ALDH1A1 (0.41) | GAASIGMAR1ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL13434257 | 0.80 | L3MBTL1 (0.41) | SIGMAR1ALDH1A1L3MBTL1LMNAKMT2A | |
| SCHEMBL13434256 | 0.80 | L3MBTL1 (0.41) | SIGMAR1ALDH1A1L3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | HPGD 542/4885GAA 3041/4885SIGMAR1 354/4885 |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | HPGD 1041/4885GAA 3900/4885SIGMAR1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.